Skip to main content
    X

    Xeris Pharmaceuticals Inc (XERS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $16.70
    +0.04 (+0.24%)

    Market Cap: $3.04B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Xeris Pharmaceuticals Inc (XERS) Earnings: Report Dates and Results

    Updated Nov 5, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Xeris Pharmaceuticals (XERS) is expected to report earnings on Mar 1, 2027. In the quarter ended Sep 30, 2026, Xeris Pharmaceuticals reported EPS of $0.06, above the $0.02 estimate. It beat the EPS estimate in 4 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    41%(14/34)
    Avg Surprise
    +1.34%
    Streak
    1 Q

    Upcoming Estimates

    Reports Mar 1, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$0.04
    Range$0.00 - $0.06
    9 analysts
    Revenue Consensus
    $120.99M
    Range$114.76M - $127.58M
    8 analysts
    Reports May 5, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$0.03
    Range$0.02 - $0.04
    2 analysts
    EPS Revisions
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$0.04-14.3%
    60d ago$0.04-14.3%
    30d ago$0.03+20.0%
    7d ago$0.03+20.0%
    Current$0.03
    Revenue Consensus
    $115.93M
    Range$114.10M - $118.70M
    3 analysts

    Next Report

    XERS has an expected report date of Mar 1, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 33.3% below the $0.06 reported for the quarter ended Dec 31, 2025.

    XERS Earnings Call

    The latest XERS earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 34 quarters below that had an estimate, XERS beat 14, missed 18 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $107.22M, up 44.2% from $74.38M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.06$0.02$0.01 - $0.04+200.00%Beat+1614.3%30 up, 1 downNov 5, 2026$107.22M
    Jun 30, 2026-$0.01$0.02-$0.01 - $0.02-150.00%MissN/A31 up, 0 downAug 6, 2026$92.10M
    Mar 31, 2026$0.01-$0.01-$0.02 - $0.01+200.00%BeatN/A30 up, 0 downMay 7, 2026$83.13M
    Dec 31, 2025$0.06$0.02$0.02 - $0.07+261.45%BeatN/A21 up, 0 downMar 2, 2026$85.81M
    Sep 30, 2025$0.00$0.01-$0.02 - $0.03-65.00%MissN/A31 up, 0 downNov 6, 2025$74.38M
    Jun 30, 2025-$0.01-$0.03-$0.03 - -$0.03+66.67%BeatN/A11 up, 0 downAug 7, 2025$71.54M
    Mar 31, 2025-$0.06-$0.04-$0.04 - -$0.04-50.00%MissN/A10 up, 0 downMay 8, 2025$60.12M
    Dec 31, 2024-$0.03-$0.02-$0.03 - -$0.01-50.00%MissN/A21 up, 0 downMar 6, 2025$60.10M
    Sep 30, 2024-$0.06-$0.08-$0.10 - -$0.06+25.00%BeatN/A60 up, 0 downNov 8, 2024$54.27M
    Jun 30, 2024-$0.10-$0.09-$0.12 - -$0.09-11.11%MissN/A61 up, 0 downAug 8, 2024$48.06M
    Mar 31, 2024-$0.14-$0.11-$0.14 - -$0.11-27.27%MissN/A60 up, 0 downMay 9, 2024$40.64M
    Dec 31, 2023-$0.10-$0.10-$0.13 - -$0.070.00%In lineN/A51 up, 0 downMar 6, 2024$44.39M
    Sep 30, 2023-$0.09-$0.10-$0.13 - -$0.09+10.00%BeatN/A50 up, 0 downNov 9, 2023$48.32M
    Jun 30, 2023-$0.14-$0.11-$0.15 - -$0.11-27.27%MissN/A40 up, 0 downAug 8, 2023$38.01M
    Mar 31, 2023-$0.12-$0.15N/A+20.00%BeatN/A40 up, 0 downMay 9, 2023$33.20M
    Dec 31, 2022-$0.10-$0.16-$0.18 - -$0.14+37.50%BeatN/A40 up, 0 downMar 8, 2023$33.14M
    Sep 30, 2022-$0.16-$0.15-$0.19 - -$0.15-6.67%MissN/A41 up, 0 downNov 9, 2022$29.73M
    Jun 30, 2022-$0.19-$0.22N/A+13.64%BeatN/AN/A0 up, 0 downAug 10, 2022$25.31M
    Mar 31, 2022-$0.25-$0.24-$0.28 - -$0.22-4.17%MissN/A50 up, 1 downMay 11, 2022$22.07M
    Dec 31, 2021-$0.42-$0.24-$0.38 - -$0.17-75.00%MissN/A50 up, 0 downMar 10, 2022$21.57M
    Sep 30, 2021-$0.39-$0.37-$0.39 - -$0.32-5.41%MissN/A30 up, 0 downNov 10, 2021$11.06M
    Jun 30, 2021-$0.41-$0.30-$0.34 - -$0.27-36.67%MissN/A3N/AAug 5, 2021$8.91M
    Mar 31, 2021-$0.30-$0.34-$0.41 - -$0.31+11.76%BeatN/A4N/AMay 13, 2021$8.05M
    Dec 31, 2020-$0.41-$0.38-$0.42 - -$0.31-7.89%MissN/A5N/AMar 9, 2021$7.17M
    Sep 30, 2020-$0.35-$0.52-$0.57 - -$0.47+32.69%BeatN/A5N/ANov 9, 2020$9.40M
    Jun 30, 2020-$0.63-$0.73-$0.80 - -$0.65+13.70%BeatN/A5N/AAug 10, 2020$2.03M
    Mar 31, 2020-$0.89-$0.89-$1.11 - -$0.810.00%In lineN/A5N/AMay 7, 2020$1.79M
    Dec 31, 2019-$1.23-$1.13-$1.31 - -$0.90-8.85%MissN/A5N/AMar 11, 2020$1.86M
    Sep 30, 2019-$1.22-$1.23-$1.36 - -$1.16+0.81%BeatN/A4N/ANov 7, 2019$323000
    Jun 30, 2019-$1.28-$0.94-$0.98 - -$0.87-36.17%MissN/A4N/AAug 6, 2019$320000
    Mar 31, 2019-$1.07-$0.76-$0.92 - -$0.68-40.79%MissN/A4N/AMay 9, 2019$248000
    Dec 31, 2018-$0.98-$0.93-$1.22 - -$0.80-5.38%MissN/A4N/AMar 6, 2019$801000
    Sep 30, 2018-$0.71-$0.78-$0.97 - -$0.71+8.97%BeatN/A4N/ANov 7, 2018$582000
    Jun 30, 2018-$3.07-$0.88-$1.13 - -$0.66-248.86%MissN/A4N/AAug 13, 2018$819000
    Mar 31, 2018-$4.69N/AN/AN/AN/AN/AN/AN/AJun 21, 2018$263000
    Dec 31, 2017-$1.29N/AN/AN/AN/AN/AN/AN/AMar 30, 2018$467000
    Sep 30, 2017-$4.43N/AN/AN/AN/AN/AN/AN/ADec 31, 2017$170000
    Jun 30, 2017-$3.72N/AN/AN/AN/AN/AN/AN/ASep 30, 2017$565000
    Mar 31, 2017-$0.23N/AN/AN/AN/AN/AN/AN/AJun 29, 2017$354000
    Dec 31, 2016-$2.29N/AN/AN/AN/AN/AN/AN/AMar 30, 2017$1.07M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$0.01, after -$0.33 the year before. It was -$2.29 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$0.01N/A
    Dec 31, 2024-$0.33N/A
    Dec 31, 2023-$0.45N/A
    Dec 31, 2022-$0.70N/A
    Dec 31, 2021-$1.52N/A
    Dec 31, 2020-$2.28N/A
    Dec 31, 2019-$4.80N/A
    Dec 31, 2018-$9.45N/A
    Dec 31, 2017-$9.67N/A
    Dec 31, 2016-$2.29N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,300 words across 9 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20264,2619
    2026Q2Jun 30, 20264,55010
    2026Q1Mar 31, 20263,5739
    2025Q4Dec 31, 20254,57111
    2025Q3Sep 30, 20254,06210
    2025Q2Jun 30, 20253,1068
    2025Q1Mar 31, 20253,4688
    2024Q4Dec 31, 20245,67010

    2026Q3 Earnings Call

    Opening remarks

    Cristi Barnett Vice President of Investor Relations Thank you, Bella. Good morning, everyone, and welcome to Xeris Biopharma's Third Quarter 2026 Financial Results Conference Call. Earlier this morning, we issued a press release detailing our third quarter 2026 financial and operating results. This press release can be found on our website at xerispharma.com. Joining me on today's call are John Shannon, our Chairman and Chief Executive Officer, and Steve Pieper, our Chief Financial Officer. Following our prepared remarks, we will open the call for your questions. Before we begin, I'd like to remind you that today's discussion will include forward-looking statements regarding Xeris' future expectations, plans, strategies, objectives, and financial performance, including our full year 2026 financial guidance and our 2030 outlook. These forward-looking statements are based on management's current assumptions and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied. For a discussion of these risks and uncertainties, please refer to the risk factors described in our filings with the SEC, including our most recent annual report on Form 10-K and our subsequent filings with the SEC, as well as the forward-looking statements disclaimer in our earnings release. In addition, during today's call, we will reference certain financial measures that are presented on a non-GAAP basis. A reconciliation of these non-GAAP measures to the most directly comparable GAAP measures is included in our earnings release. Before I turn it over to John, I'd like to briefly introduce myself. I'm Cristi Barnett, and I recently joined Xeris to lead investor relations following Allison Wey's retirement. Some of you may know me from my previous companies, and for those who I haven't yet met, I look forward to connecting and working with you. We will miss Allison here at Xeris, and I'm pleased to carry the investor relations baton forward. I look forward to an open dialogue and to keeping you informed about Xeris' progress. With that, I'll turn it over to John.

    John Shannon Chairman and CEO Thank you, Cristi, and welcome to Xeris. We are happy to have you on the team. Good morning, everyone. I am pleased to report that Xeris had a spectacular third quarter, and we now see our company on a new growth curve, one that is both accelerating our near-term financial outlook and redefining what we believe is possible for this company. Importantly, this new trajectory reflects expected growth from the entire enterprise, Recorlev, Gvoke, and KEVEYIS. Total revenue grew more than 44% year-over-year, led by Recorlev, where the expanded commercial team moved from build to yield and delivered record referrals and new patient starts. Gvoke delivered a better-than-expected back-to-school prescription lift, and prescription demand is back in solid growth mode.

    Frequently Asked Questions About XERS

    When is Xeris Pharmaceuticals's next earnings date?

    Xeris Pharmaceuticals's next earnings report is expected for Mar 1, 2027.

    Did XERS beat earnings estimates last quarter?

    Yes. Xeris Pharmaceuticals reported EPS of $0.06 for the quarter ended Sep 30, 2026, above the $0.02 estimate, a 200.00% surprise.

    What EPS do analysts expect from XERS next quarter?

    The consensus EPS estimate for Xeris Pharmaceuticals for the quarter ending Dec 31, 2026 is $0.04 from 9 analysts, with estimates from $0.00 to $0.06.

    How often does XERS beat earnings estimates?

    Xeris Pharmaceuticals beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of +51.64%.